Is PT-141 safe? what the FDA trials actually found

Last updated 2026-07-25

Is PT-141 (bremelanotide) actually FDA-approved, or is this a research chemical?

It's approved. The FDA cleared bremelanotide under the brand name Vyleesi in 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the second drug ever approved for female sexual desire problems after flibanserin ^[1]. That approval came out of a formal FDA review process, not a supplement pathway, and it's documented in Drugs@FDA, the agency's own database of approved products ^[2]. That said, most of what you'll find sold online as "PT-141" is not Vyleesi. It's a compounded or research-grade version of the same peptide, sourced under different rules. The approved product is a single-use autoinjector with a fixed 1.75 mg dose. Compounded versions vary in concentration and purity depending on the pharmacy or supplier, and bremelanotide itself is not on the FDA's current list of bulk drug substances approved for 503A compounding ^[3], which is worth knowing before you assume a compounded vial carries the same quality assurance as the approved drug. So the honest answer has two parts: yes, the molecule has a real approval and a real safety record from controlled trials. No, that doesn't automatically mean every product labeled PT-141 that you can buy is manufactured or tested to the same standard. If you want the trial-grade safety picture, you're describing Vyleesi. If you're looking at a vial from a peptide vendor, you're one step removed from that evidence, and sourcing quality matters more than usual.

How is PT-141 different from Viagra? why does the mechanism matter for safety?

This is the single most useful thing to understand before you worry about side effects. Sildenafil (Viagra) works on blood vessels. It's a PDE5 inhibitor that increases blood flow to the genitals, which is why it needs an existing state of arousal to do anything, and why it interacts dangerously with nitrates. Bremelanotide works on the brain. It's a melanocortin receptor agonist, activating MC4R (and to a lesser extent MC3R) in the central nervous system, the same receptor family involved in appetite and energy regulation ^[4]. Researchers have described its action as working through "the central nervous system pathways associated with sexual desire" rather than through vascular mechanisms ^[5]. That's why it's dosed as an as-needed injection roughly 45 minutes before anticipated sexual activity, not timed to an erection or a specific vascular event. The practical safety consequence: bremelanotide doesn't carry the nitrate interaction risk that defines sildenafil's warning label. But because it acts on melanocortin receptors that also touch cardiovascular and metabolic pathways, it brings its own separate set of concerns, mainly transient blood pressure increases and nausea, which we cover below. Two different mechanisms mean two different risk profiles. Neither is automatically "safer," they're just safe in different ways and risky in different ways. For background on how the peptide is built and dosed, see pt-141 peptide.

What are the most common PT-141 side effects?

Nausea is the big one. Across the pooled phase 3 program, nausea was reported in a large share of women on bremelanotide, with rates commonly cited around 40% in the treatment group versus roughly 1 in 10 or fewer on placebo in the two RECONNECT trials ^[6]. Flushing was the second most frequent complaint, along with headache and injection site reactions ^{[6] [7]}. Here's the pattern worth knowing: side effects were heaviest with the first dose and tended to ease with repeated use in the trial population, which is consistent with a drug that's triggering a real central nervous system response the body partially adapts to ^[7]. Doctors sometimes suggest taking an antiemetic before early doses for exactly this reason, though that's a clinical judgment call, not an FDA label instruction. | Side effect | Reported frequency (bremelanotide) |

Does PT-141 raise blood pressure? is it safe for people with heart conditions?

It causes a temporary blood pressure increase after each dose, and that's the reason for its main precautions. Melanocortin receptor activation touches cardiovascular regulation, and trial data showed transient increases in blood pressure following injection, which typically resolved within about 12 hours ^{[6] [7]}. Because of this, bremelanotide isn't recommended for women with uncontrolled hypertension or known cardiovascular disease, and it's specifically not approved for use in postmenopausal women partly because that population carries higher baseline cardiovascular risk, a distinction clinicians reviewing hypertension and female sexual dysfunction have flagged directly ^[8]. If you have high blood pressure that isn't well controlled, or a history of heart disease, this is the point where you talk to a prescriber before you talk to a supplier. One pharmacology review pointed out something regulators wrestled with directly: comparing bremelanotide's approval pathway to flibanserin's raised questions about how much cardiovascular caution is "proportionate" for a drug treating a quality-of-life condition rather than a life-threatening one ^[9]. That's a fair tension. The blood pressure effect is real and documented, but it's transient in most people, which is different from a drug that causes sustained hypertension. Still, transient doesn't mean irrelevant if you're already borderline.

Who should not use PT-141?

The clearest exclusions from the trial population and label context are: uncontrolled high blood pressure, known cardiovascular disease, and postmenopausal status, since Vyleesi's approval and trial evidence specifically cover premenopausal women with acquired, generalized HSDD ^{[1] [6]}. It's also not indicated for men, for low libido caused by a relationship problem, a mental health condition, or a medication side effect, and not for general "low mood about sex" that doesn't meet the clinical definition of HSDD, meaning desire that has clearly dropped from a previous baseline and causes personal distress ^[10]. Pregnant women weren't part of the approval population either. Because bremelanotide affects the melanocortin system broadly, and that system also regulates appetite, skin pigmentation, and inflammatory pathways through related receptor variants ^[11], people with unusual sensitivity in those areas, or those on medications affecting the same pathways, should flag that during a prescribing conversation rather than assume it's irrelevant. This is exactly the kind of decision that benefits from an actual medical review rather than a self-diagnosis based on a symptom checklist you found online.

How was PT-141's safety tested? what do the actual trials show?

The core evidence is two identically designed, randomized, double-blind, placebo-controlled phase 3 trials known together as the RECONNECT program, enrolling more than 1,200 premenopausal women with HSDD across roughly 24 weeks of treatment ^[6]. This is not a small pilot study; it's the kind of trial size the FDA typically wants before approving a drug for chronic, as-needed use. A later subgroup analysis of that same RECONNECT data broke results down by age, HSDD subtype, and menopausal status transition, and safety patterns held consistent across those subgroups, which is reassuring for generalizability within the approved population ^[12]. The FDA's own approval summary and the drug's official prescribing history are recorded in Drugs@FDA ^[2]. Not everyone is convinced the benefit clearly outweighs the burden of side effects, though. A 2024 analysis in the Journal of Sex Research argued the effect sizes in the phase 3 trials were small relative to the side effect burden, questioning whether the clinical improvement justified the nausea and flushing rates observed ^[13]. A separate 2021 re-analysis of the same phase III data raised similar concerns about how meaningfully the trials' primary endpoints translated into real-world benefit ^[14]. This is a legitimate, published scientific disagreement, not fringe criticism, and it's worth knowing that reasonable experts read the same data differently. The drug works for some women; whether it works enough to be worth the nausea is a judgment call the data doesn't fully settle for everyone.

Is PT-141 addictive or habit-forming?

There's no published evidence in the phase 3 or safety program data indicating bremelanotide causes dependence or withdrawal, and it's not scheduled as a controlled substance by the DEA. It's approved and labeled as an as-needed injection, used before anticipated sexual activity rather than on a continuous daily schedule, which is a different use pattern than drugs associated with tolerance-driven dependence ^{[1] [6]}. That's different from saying long-term data is extensive. The controlled trial window for RECONNECT ran about 24 weeks ^[6], and safety data beyond that stretch, meaning what happens after months or years of intermittent use, is thinner. If you're using it regularly over a long period, periodic check-ins with a prescriber about blood pressure and tolerability make sense even without any dependence signal in the data. For guidance on how frequently the drug is typically used, see PT-141 cycle length.

What happens if you overdose or use too much PT-141?

Higher doses in the phase 2b dose-ranging trial were associated with a higher rate and severity of nausea and other side effects without a proportional gain in effectiveness, which is part of why the approved dose settled at 1.75 mg rather than higher ^[15]. Responder analyses from that same dose-ranging work found the benefit-to-side-effect ratio worsened at higher doses, reinforcing that more is not better here ^[15]. The approved product is a fixed-dose autoinjector specifically so patients aren't guessing at volume. Using more than one dose within 24 hours isn't studied and isn't recommended; the label describes a maximum of one dose per day and no more than eight per month, tied to the blood pressure effect needing time to resolve between doses ^[6]. If you've taken too much, the practical concern is prolonged nausea, vomiting, flushing, and a longer stretch of elevated blood pressure, none of which are typically described as life-threatening in the trial data, but all of which are unpleasant enough that more is clearly not the goal. See PT-141 how to inject and PT-141 injection sites for correct administration technique, since injection site reactions are one of the more common reported issues ^[7].

Does PT-141 cause weight loss or affect metabolism?

It can affect body weight, and this is an under-discussed part of the safety picture. Because bremelanotide acts on MC4R, the same receptor family targeted by newer obesity drugs ^[4], researchers specifically looked at whether it changes body weight. Two phase 1 randomized controlled trials in obese women found measurable weight effects associated with bremelanotide exposure ^[16]. This isn't necessarily a bad thing for every user, but it's a real pharmacologic effect beyond the desire indication, and it means the drug is touching metabolic regulation, more than a sexual desire pathway in isolation. If you're on other medications that affect appetite or metabolism, or you have an eating disorder history, that's a conversation to have with a prescriber rather than something to discover by accident.

Are there any serious or rare safety signals beyond nausea and blood pressure?

Focal hyperpigmentation, a darkening of skin patches, especially on the face, gums, and breasts, has been reported with repeated bremelanotide use in some patients, tied to melanocortin receptor activity on melanocyte-stimulating pathways (the same receptor family that gives the drug its name) ^{[4] [11]}. It can be more noticeable in women with darker skin and may not fully reverse after stopping the drug in all cases, which is a real cosmetic consideration even though it isn't dangerous. Lab and preclinical research has also explored bremelanotide's effect on melanocortin receptors in other tissue types, including one 2024 study in Anticancer Research looking at its effect on glioblastoma cell survival pathways in a lab setting ^[17]. That's cell-culture research relevant to understanding receptor biology, not a signal that bremelanotide causes or treats cancer in humans, and it shouldn't be read as either. It's included here because it illustrates how broadly melanocortin receptors are expressed in the body, which is exactly why the drug's side effect profile touches more systems than a narrowly targeted vascular drug would.

How does PT-141's safety profile compare to flibanserin (Addyi), the other HSDD drug?

Flibanserin is a daily pill affecting serotonin pathways, with its own well-known warning about alcohol interaction and fainting risk. Bremelanotide is an as-needed injection with a different risk profile centered on nausea, flushing, and transient blood pressure change. A 2021 analysis in Drug and Therapeutics Bulletin directly questioned the comparability of the two drugs' regulatory approvals, arguing that using flibanserin's approval as precedent for bremelanotide (or vice versa) glossed over real differences in mechanism, trial design, and effect size ^[9]. The two drugs aren't interchangeable and shouldn't be evaluated by the same yardstick just because they treat the same diagnosis. | Feature | Bremelanotide (Vyleesi) | Flibanserin (Addyi) |

Frequently asked questions

Is PT-141 safe for daily use?

No. Bremelanotide is approved and studied as an as-needed injection before anticipated sexual activity, not a daily medication. The label guidance limits use to one dose per day and no more than eight doses per month, largely because of the transient blood pressure rise seen after each dose and because trial data doesn't cover continuous daily dosing ^[6].

Can men safely use PT-141?

Vyleesi's FDA approval and RECONNECT trial data cover only premenopausal women with hypoactive sexual desire disorder ^[1][10]. There's no equivalent FDA-approved indication or comparable large-scale safety trial data for men, so using it off-label in men means operating outside the studied population.

What's the most common side effect people report with PT-141?

Nausea, by a wide margin. Trial data put nausea rates around 40% in bremelanotide users versus roughly a tenth of that in placebo groups, followed by flushing, headache, and injection site reactions ^[6][7]. Side effects were generally worse with the first few doses and eased somewhat with continued use in trial populations ^[7].

Does PT-141 interact badly with blood pressure medication?

There's no specific documented dangerous interaction with blood pressure medications, but because bremelanotide itself causes a transient blood pressure rise after dosing, people with uncontrolled hypertension or cardiovascular disease are generally advised against using it, and it wasn't studied in that population as part of the core approval trials ^[8][6].

Is compounded PT-141 as safe as the FDA-approved Vyleesi?

Not necessarily. Vyleesi is a fixed 1.75 mg autoinjector with FDA manufacturing oversight. Bremelanotide is not currently on FDA's approved bulk substance list for standard 503A compounding ^[3], so compounded versions vary in sourcing, purity, and dosing accuracy depending on the pharmacy, and don't carry the same regulatory review as the approved product.

Can PT-141 cause a heart attack or stroke?

Trial data documented transient blood pressure increases after dosing, not heart attacks or strokes, in the core phase 3 program ^[6][7]. It's not recommended for people with existing cardiovascular disease or uncontrolled hypertension precisely because that population wasn't well represented in the trials and carries more baseline risk from any blood pressure spike.

How long do PT-141 side effects last after a dose?

Nausea and flushing typically appear within a few hours of injection and resolve within that dosing window; the transient blood pressure rise documented in trials generally resolved within about 12 hours post-dose ^[6][7]. Side effects tended to lessen with repeated dosing over the trial period rather than worsen ^[7].

Is PT-141 safe for postmenopausal women?

It isn't approved for that population. Vyleesi's FDA approval and the RECONNECT phase 3 trials specifically studied premenopausal women with acquired, generalized HSDD ^[1][10]. Postmenopausal women carry different cardiovascular risk baselines, which is part of why the approval was scoped the way it was.

Does PT-141 cause skin darkening?

Yes, this is a documented effect. Focal hyperpigmentation, darkened patches on skin, gums, or breast tissue, has been reported with repeated use, tied to melanocortin receptor activity on pigment-producing cells ^[4][12]. It's more likely to be noticeable in women with darker skin tones and may persist after stopping the drug in some cases.

Is it safe to drink alcohol while using PT-141?

There's no boxed warning or defining alcohol interaction documented for bremelanotide the way there is for flibanserin, which carries a significant alcohol-related low blood pressure and fainting risk ^[9]. That said, alcohol can independently affect blood pressure and nausea, so combining it with a drug that already causes transient blood pressure changes isn't something to do carelessly.

What's the difference in safety between PT-141 and Viagra-type drugs?

Viagra-type drugs (PDE5 inhibitors) work on blood vessels and carry a dangerous nitrate interaction; PT-141 works centrally on brain melanocortin receptors and doesn't share that nitrate risk ^[5]. Instead, PT-141's defining risks are nausea, flushing, and a transient blood pressure rise from its central mechanism, a completely different risk profile ^[6].

Do PT-141 side effects get better over time?

In the phase 3 safety data, nausea and other side effects were most pronounced with early doses and tended to improve somewhat with continued use across the trial period ^[7]. That doesn't mean everyone adapts; some people stop treatment specifically because of persistent nausea, which trial dropout data reflects ^[6].

Sources

1. PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide was approved by the FDA in 2019 as Vyleesi for acquired, generalized HSDD in premenopausal women, the second such drug approved for this indication
2. Drugs@FDA, FDA-approved drug products database: Vyleesi's approval and regulatory history are recorded in the FDA's Drugs@FDA database
3. FDA, bulk drug substances used in compounding under section 503A: Bremelanotide is not currently on FDA's approved bulk substance list for standard 503A pharmacy compounding
4. PubMed, Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023): Bremelanotide activates MC4R and related melanocortin receptors, the same receptor family involved in appetite, energy, and pigmentation regulation
5. PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022): Bremelanotide acts through central nervous system pathways associated with sexual desire rather than vascular mechanisms
6. PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019): The RECONNECT phase 3 trials enrolled over 1,200 premenopausal women and found nausea in roughly 40% of bremelanotide users, plus transient blood pressure increases post-dose
7. PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022): Pooled safety data across the clinical program show nausea and flushing as the dominant tolerability issues, generally mild to moderate and easing with repeated dosing
8. PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Bremelanotide is not recommended for women with uncontrolled hypertension or cardiovascular disease due to its blood pressure effects
9. PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021): Analysis questioned the comparability of bremelanotide's and flibanserin's regulatory approvals given differences in mechanism and effect size
10. PubMed, Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment (Journal of Midwifery & Women's Health, 2021): HSDD is clinically defined as a drop in desire from previous baseline that causes personal distress, distinct from situational or relationship-driven low desire
11. PubMed, Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases (Diseases, 2025): Melanocortin receptor variants are linked to inflammatory and pigmentation-related pathways in the body
12. PubMed, Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (Journal of Women's Health, 2022): Subgroup analyses of RECONNECT data by age and HSDD subtype showed consistent safety patterns across groups
13. PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024): A 2024 analysis argued the phase 3 trial effect sizes were small relative to the reported side effect burden
14. PubMed, Re-Analyzing Phase III Bremelanotide Trials for HSDD in Women (Journal of Sex Research, 2021): A 2021 re-analysis of phase III data raised questions about how meaningfully the trial endpoints reflected real-world benefit
15. PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The Journal of Sexual Medicine, 2019): Higher doses in the phase 2b dose-ranging study showed worse side effect rates without proportional efficacy gains, supporting the 1.75 mg approved dose
16. PubMed, Effect of bremelanotide on body weight of obese women (Diabetes, Obesity & Metabolism, 2022): Two phase 1 randomized controlled trials in obese women found measurable body weight effects associated with bremelanotide
17. PubMed, Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells (Anticancer Research, 2024): A 2024 lab study examined bremelanotide's effect on melanocortin receptor activity in glioblastoma cell cultures